These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 26386029)

  • 1. Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia.
    Camargo JF; Simkins J; Beduschi T; Tekin A; Aragon L; Pérez-Cardona A; Prado CE; Morris MI; Abbo LM; Cantón R
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5903-8. PubMed ID: 26386029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.
    Shields RK; Nguyen MH; Chen L; Press EG; Potoski BA; Marini RV; Doi Y; Kreiswirth BN; Clancy CJ
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta--lactamase-producing Klebsiella pneumoniae epidemic clone.
    Cobo J; Morosini MI; Pintado V; Tato M; Samaranch N; Baquero F; Cantón R
    Diagn Microbiol Infect Dis; 2008 Mar; 60(3):319-22. PubMed ID: 17996417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic strategy for pandrug-resistant Klebsiella pneumoniae severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen.
    Oliva A; Mascellino MT; Cipolla A; D'Abramo A; De Rosa A; Savinelli S; Ciardi MR; Mastroianni CM; Vullo V
    Int J Infect Dis; 2015 Apr; 33():132-4. PubMed ID: 25597275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit.
    Sbrana F; Malacarne P; Viaggi B; Costanzo S; Leonetti P; Leonildi A; Casini B; Tascini C; Menichetti F
    Clin Infect Dis; 2013 Mar; 56(5):697-700. PubMed ID: 23155147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Over-treatment of carbapenemase-producing Enterobacteriaceae.
    Rihani DS; Wallace MR; Sieger BE; Waite RA; Fox M; Brown SA; Deryke CA
    Scand J Infect Dis; 2012 May; 44(5):325-9. PubMed ID: 22200121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical issues for Klebsiella pneumoniae KPC-carbapenemase producing K. pneumoniae infections: a critical agenda.
    De Rosa FG; Corcione S; Cavallo R; Di Perri G; Bassetti M
    Future Microbiol; 2015; 10(2):283-94. PubMed ID: 25689539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
    Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
    Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?
    Del Bono V; Giacobbe DR; Marchese A; Parisini A; Fucile C; Coppo E; Marini V; Arena A; Molin A; Martelli A; Gratarola A; Viscoli C; Pelosi P; Mattioli F
    Virulence; 2017 Jan; 8(1):66-73. PubMed ID: 27430122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae.
    Giamarellou H; Galani L; Baziaka F; Karaiskos I
    Antimicrob Agents Chemother; 2013 May; 57(5):2388-90. PubMed ID: 23439635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia.
    Shields RK; Nguyen MH; Potoski BA; Press EG; Chen L; Kreiswirth BN; Clarke LG; Eschenauer GA; Clancy CJ
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1797-801. PubMed ID: 25534733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections.
    Oliva A; D'Abramo A; D'Agostino C; Iannetta M; Mascellino MT; Gallinelli C; Mastroianni CM; Vullo V
    J Antimicrob Chemother; 2014 Jun; 69(6):1718-20. PubMed ID: 24521856
    [No Abstract]   [Full Text] [Related]  

  • 14. Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective.
    Daikos GL; Markogiannakis A; Souli M; Tzouvelekis LS
    Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1393-404. PubMed ID: 23253318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection.
    Hirsch EB; Tam VH
    J Antimicrob Chemother; 2010 Jun; 65(6):1119-25. PubMed ID: 20378670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?
    Daikos GL; Markogiannakis A
    Clin Microbiol Infect; 2011 Aug; 17(8):1135-41. PubMed ID: 21635663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbiological and molecular characteristics of carbapenemase-producing Klebsiella pneumoniae endemic in a tertiary Greek hospital during 2004-2010.
    Zagorianou A; Sianou E; Iosifidis E; Dimou V; Protonotariou E; Miyakis S; Roilides E; Sofianou D
    Euro Surveill; 2012 Feb; 17(7):. PubMed ID: 22370015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia.
    Song W; Moland ES; Hanson ND; Lewis JS; Jorgensen JH; Thomson KS
    J Clin Microbiol; 2005 Sep; 43(9):4891-4. PubMed ID: 16145169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of NDM-1 Klebsiella pneumoniae bacteraemia in a neutropenic patient.
    Chien JM; Koh TH; Chan KS; Chuah TH; Tan TT
    Scand J Infect Dis; 2012 Apr; 44(4):312-4. PubMed ID: 22126430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of tigecycline resistance in Klebsiella pneumoniae in a single patient.
    Al-Qadheeb NS; Althawadi S; Alkhalaf A; Hosaini S; Alrajhi AA
    Ann Saudi Med; 2010; 30(5):404-7. PubMed ID: 20697161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.